KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.

Indranil Dasgupta, Amy M Meadowcroft, Purav R Bhatt, Anjali Acharya, Michael Aarup, Ricardo Correa-Rotter, Shruti Gupta, Vijay K Kher, Osvaldo M Viera Neto, Anjay Rastogi, Mai Ots-Rosenberg, Brian Rayner, Muh Geot Wong, Sunay Shah, Lin Taft, Ajay K Singh

Nephrol Dial Transplant 40(7) 1332-1341

PMID39817409
PMCIDPMC12207604
DOI10.1093/ndt/gfae273
发表日期2025-01-16
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND AND HYPOTHESIS: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD). METHODS: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients). In PD patients, prespecified analyses of the co-primary endpoints of mean change in hemoglobin from baseline to Weeks 28-52 using an ANOVA model and first occurrence of a major cardiovascular event (MACE) using a Cox proportional hazards model were conducted. The secondary endpoints were average monthly intravenous iron dose to Week 52 and treatment-emergent adverse events. Additional post hoc analyses were conducted. RESULTS: Overall, 340 PD patients (daprodustat n = 171, darbepoetin alfa n = 169) were randomized. Mean age was 53.6 years (±14 SD), 55% male, 56% White. For daprodustat and darbepoetin alfa groups respectively, mean change in hemoglobin was 0.38 and 0.23 g/dL [adjusted mean difference 0.15, 95% confidence interval (CI), -0.04, 0.34], and first occurrence of adjudicated MACE occurred in 40 (23.4%) and 46 (27.2%) patients (HR 0.84; 95% CI, 0.55-1.28). No heterogeneity was observed between PD and HD patients for these endpoints in ASCEND-D. Serum hepcidin was lower with daprodustat; there was no difference in other iron parameters, intravenous iron usage, transfusion requirement, blood pressure, or quality of life. There were no differences in adverse events or incidence of peritonitis between the groups. CONCLUSIONS: This subgroup analysis of the ASCEND-D trial demonstrated comparable efficacy and safety of daprodustat versus darbepoetin alfa in PD patients, supporting its use in the treatment of anemia in these patients.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 2

Figure 2: Kaplan–Meier plots of post hoc time to first occurrence of adjudicated cardiovascular events, death from any cause, and hospitalization from any cause in patients undergoing PD. Patients at risk were all randomized patients. Dapro, daprodustat; Darbe, darbepoetin alfa.

A

Time to first occurrence of adjudicated MACE

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start
查看结果
B

Time to adjudicated all-cause mortality

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start
查看结果
C

Time to first occurrence of adjudicated cardiovascular death or non-fatal myocardial infarction

Figure 2 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

Time to first occurrence of all-cause hospitalization

Figure 2 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1: Prespecified analysis of change in hemoglobin (Hb) from baseline over time in patients undergoing PD. Error bars show 95% CI. Post-randomization values include on- and off-treatment values. Dashed vertical lines represent the evaluation period (Week 28 to Week 52). Wk, week; EOS, end of study; FU; follow-up. Dapro, daprodustat; Darbe, darbepoetin alfa.
非 KM Figure
Figure 3Figure 3: Post hoc on-treatment iron markers over time in patients undergoing PD, peritoneal dialysis.
非 KM Figure